TFCP2 Gene (Alpha-Globin Transcription Factor CP2)
Transcriptional regulator involved in erythroid development, cell cycle control, and oncogenesis.
Gene Information Card
| Symbol | TFCP2 |
|---|---|
| Full Name | Transcription factor CP2 |
| Gene Type | Protein coding |
| Chromosomal Location | 12q13.12 |
| NCBI Gene ID | 7024 ncbi.nlm.nih.gov/gene/7024 |
| Ensembl ID | ENSG00000135457 |
| UniProt ID | Q12800 |
| OMIM ID | 189889 |
| HGNC ID | 11749 |
| Aliases | LSF, SEF, TFCP2C, CP2, LBP-1c |
Description
TFCP2 (Transcription Factor CP2) encodes a member of the CP2 family of transcription factors. The protein binds to the alpha-globin promoter and regulates erythroid gene expression. It also functions in cell cycle control, differentiation, and has been implicated in viral transcription (e.g., HIV-1 LTR). TFCP2 is involved in both transcriptional activation and repression, and its dysregulation is associated with several cancers.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Hepatocellular carcinoma | TFCP2 overexpression promotes cell proliferation and metastasis via transcriptional activation of target genes. | COSMIC; PMID: 25619955 |
| Colorectal cancer | TFCP2 upregulation correlates with poor prognosis and enhances Wnt/β-catenin signaling. | COSMIC; PMID: 28341829 |
| Prostate cancer | TFCP2 acts as an oncogene by regulating androgen receptor signaling and cell cycle genes. | COSMIC; PMID: 23382210 |
| Breast cancer | TFCP2 overexpression associated with aggressive tumor phenotypes and chemoresistance. | COSMIC; PMID: 25944712 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 15.2 | Medium |
| Bone marrow | 12.8 | Medium |
| Lung | 9.5 | Low |
| Colon | 8.1 | Low |
| Prostate | 7.3 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 14.5 | Hepatocellular carcinoma cell line |
| K562 | 11.2 | Erythroleukemia cell line |
| MCF7 | 8.9 | Breast cancer cell line |
| PC3 | 7.6 | Prostate cancer cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015C>T (p.Arg339Trp) | Missense | <0.1% | Altered DNA-binding affinity; reported in COSMIC |
| c.1246G>A (p.Glu416Lys) | Missense | <0.1% | Unknown functional impact; rare population variant |
| c.1480_1481insA (p.Thr494Asnfs*12) | Frameshift | <0.1% | Predicted loss of function; truncation |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations (e.g., p.Thr494Asnfs*12) are predicted to cause loss of function via protein truncation.
Gain of Function (GOF)
Overexpression and amplification of TFCP2 in multiple cancers suggest gain-of-function oncogenic activity, though specific activating point mutations are not well characterized.
Dominant Negative (DN)
No dominant-negative mutations have been reported for TFCP2 in curated databases.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Erythropoiesis (alpha-globin gene regulation)
• Wnt/β-catenin signaling (in cancer)
• Androgen receptor signaling (prostate cancer)
Protein Summary
TFCP2 (also known as LSF) is a 502-amino acid transcription factor containing a CP2-type DNA-binding domain. It forms homo- or heterodimers with other CP2 family members (e.g., TFCP2L1) and binds to the consensus sequence CNRGN(N)5CNRGN. The protein regulates genes involved in erythroid differentiation, cell cycle progression, and apoptosis. Post-translational modifications include phosphorylation and sumoylation, which modulate its activity. In cancer, TFCP2 is frequently overexpressed and promotes tumor growth, invasion, and metastasis.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TFCP2 Knockout HEK293 Cell Line | EDJ-KQ5920 | Human | 7024 | Details Get a Quote |
| TFCP2L1 Knockout HEK293 Cell Line | EDJ-KQ9057 | Human | 29842 | Details Get a Quote |
| TFCP2 Knockout A-549 Cell Line | EDJ-KQ29453 | Human | 7024 | Details Get a Quote |
| TFCP2 Knockout HCT 116 Cell Line | EDJ-KQ29454 | Human | 7024 | Details Get a Quote |
| TFCP2 Knockout HeLa Cell Line | EDJ-KQ29455 | Human | 7024 | Details Get a Quote |
| TFCP2L1 Knockout A-549 Cell Line | EDJ-KQ35517 | Human | 29842 | Details Get a Quote |
| TFCP2L1 Knockout HCT 116 Cell Line | EDJ-KQ35518 | Human | 29842 | Details Get a Quote |
| TFCP2L1 Knockout HeLa Cell Line | EDJ-KQ56111 | Human | 29842 | Details Get a Quote |
